期刊文献+

Gremlin-1在前列腺癌中的作用研究进展

Research progress on the role of Gremlin-l in prostate cancer
下载PDF
导出
摘要 前列腺癌(prostaticcancer, PCa)是老年男性最常见的生殖系统恶性肿瘤之一。前列腺癌在2023年美国预计出现的癌症病人的罹患率中位列第一位,达到29%[1]。PCa的死亡病例数在中国2020年男性癌症死亡病例中位列第七,达到5万人[2]。在中国, PCa在整个社会的癌症负担中所占比例仍较低,但随着人口老龄化进展和早期诊疗技术发展,其所带来的社会医疗卫生负担将不容小觑。
作者 张旭泓 崔心刚 Zhang Xuhong;Cui Xingang
出处 《老年医学与保健》 CAS 2023年第4期852-856,共5页 Geriatrics & Health Care
  • 相关文献

参考文献7

二级参考文献87

  • 1Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016 [J]. CACancer J Clin, 2016, 66(1): 7-30.
  • 2Chen W, Zheng R, Baade P D, et al. Cancer statistics in China,2015[J], CA Cancer J Clin, 2016, 66(2):115-132.
  • 3Chopra S, Rashid P. Management of castration-resistant (ad-vanced) prostate cancer (CRPC): rationale, progress and futuredirections[J].Aust Fam Physician, 2015, 44(5): 302-305.
  • 4Molina A, Belldegrun A. Novel therapeutic strategies for castrationresistant prostate cancer: inhibition of persistent androgen pro-duction and androgen receptor mediated signalingfj]. J Urol, 2011,185(3):787-794.
  • 5Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalu-tamide in prostate cancer after chemotherapy[J]. N Eng丨 J Med,2012,367(13):1187-1197.
  • 6Pienta K J. Preclinical mechanisms of action of docetaxel and do-cetaxel combinations in prostate cancer[J], Semin Oncol, 2001,28(4Suppl 15):3-7.
  • 7Paller C J, Antonarakis E S. Cabazitaxei: a novel second-linetreatment for metastatic castration-resistant prostate cancer [J],Drug Des Devel Ther, 2011(5):117-124.
  • 8巳ertholdD R, Pond G R, Soban F, et at. Docetaxel plus prednisoneor mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
  • 9Oudard S, Banu E, Beuzeboc P, et af. Multicenter randomizedphase It study of two schedules of docetaxel, estramustine, andprednisone versus mitoxantrone plus prednisone in patients withmetastatic hormone-refractory prostate cancer[J]. J Clin Oncol,2005, 23(15):3343-3351.
  • 10Kantoff P W, Higano C S, Shore N D, et al. Sipuleucel-T im-munotherapy for castration-resistant prostate cancer[J], N EnglJ Med, 2010, 363(5):411-422.

共引文献178

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部